In yesterday’s Wall Street session, TransCode Therapeutics Inc (NASDAQ:RNAZ) shares traded at $0.82, up 15.98% from the previous session.
RNAZ stock price is now 28.56% away from the 50-day moving average and -95.95% away from the 200-day moving average. The market capitalization of the company currently stands at $5.39M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
In other news, Dudley Robert Michael, Chief Executive Officer bought 98,000 shares of the company’s stock on Sep 28 ’23. The stock was bought for $49,980 at an average price of $0.51. Upon completion of the transaction, the Chief Executive Officer now directly owns 180,262 shares in the company, valued at $0.15 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 28 ’23, Chief Financial Officer Fitzgerald Thomas A bought 49,350 shares of the business’s stock. A total of $25,168 was incurred on buying the stock at an average price of $0.51. This leaves the insider owning 56,318 shares of the company worth $46180.76. A total of 0.53% of the company’s stock is owned by insiders.
During the past 12 months, TransCode Therapeutics Inc has had a low of $0.42 and a high of $309.60. As of last week, the company has a debt-to-equity ratio of 0.27, a current ratio of 1.28, and a quick ratio of 1.28.
TransCode Therapeutics Inc(RNAZ) Company Profile
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company’s lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
